Generic Drug Price Antitrust Litigation Expanded in Pennsylvania Court

The Eastern District of Pennsylvania has become the hub for the Generic Drug Price Fixing Antitrust Litigation. On April 7, the U.S. Judicial Panel on Multidistrict Litigation transferred several additional cases to the MDL that is pending in the Eastern District of Pennsylvania Court, expanding the scope of the litigation to include any actions related to the alleged price-fixing of generic drugs between 2012 and present.

Because of the change in scope, the name of the MDL will be changed from In re Generic Digoxin and Doxycycline Antitrust Litigation to In re Generic Pharmaceuticals Pricing Antitrust Litigation.

The class action cases stem from a federal probe into significant increases in the prices for generic drugs over the past several years. The probe led two former executives at Heritage Pharmaceuticals, Jeffery Glazer and Jason Malek, to plead guilty to price-fixing charges for manipulating drug prices.

Dianne Nast is co-lead counsel for the Plaintiffs along with Roberta Liebenberg of Fine, Kaplan and Black. Ms. Nast commented about the decision by the judicial panel: “It’s a very significant decision by the panel and certainly a vote of confidence to send this many cases, with this many defendants and this many products, to the district.”

Read the full article from the Legal Intelligencer for more information.